Increased Incidence of Recurrent Venous Thromboembolism in Patients with Cancer Receiving Bevacizumab
Jonathan E. Dowell, MD, Sarah M. Gressett Ussery, PharmD, BCOP, Kevin C. Kelly, PharmD, BCPS, Sachin R. Shah, PharmD, BCOP, FCCP, Tanis L. Welch, PharmD
Angiogenesis, the development of new blood vessels from preexisting vessels, is considered to be one of the central “hallmarks” in most malignancies.
Improving Patient Care and Medication Safety: Standardizing Antiemetic Agents in Chemotherapy Order Sets in a Large Healthcare System
The Multinational Association of Supportive Care in Cancer, the American Society of Clinical Oncology, and the National Comprehensive Cancer Network (NCCN) each publish antiemetic and supportive care guidelines for patients who are undergoing chemotherapy treatment.
A Retrospective Chart Review on the Toxicity of Pegylated Asparaginase in Adult Patients with Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia (ALL) is among the most common hematologic malignancies, with an annual incidence of 6020 patients in the United States, of which 2000 to 2500 cases occur in adults. Trends have shown an early peak between the ages of 4 and 5 years, with another increase after the age of 50 years.
Evaluation of G-CSF Use in a Single Institution and Development of Pocket Reference for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia
Chemotherapy-induced febrile neutropenia (CIFN) is a life-threatening, costly complication that may develop in patients with cancer after receiving myelosuppressive chemotherapy. In 1991, filgrastim (Neupogen) was approved for the treatment of patients with CIFN, because it stimulates the production of neutrophils, which potentially treats and prevents febrile neutropenia.
Successful Panitumumab Administration after Cetuximab-Induced Aseptic Meningitis: A Case Report and Review
Cetuximab and panitumumab, monoclonal antibodies directed against the epidermal growth factor receptor (EGFR), are an integral component in the management of patients with metastatic colorectal cancer (mCRC), specifically those with KRAS wild-type tumors.
Prostate cancer is the most common cancer in men, with an estimated 238,590 new cases diagnosed in 2013 and 29,720 deaths.
Children diagnosed with cancer undergo changes in body weight secondary to illness and treatment. With progression to malnutrition come a number of significant complications.
Most patients with cancer have multiple comorbidities and are at high risk of polypharmacy. In addition, reviews have shown that up to 33% of ambulatory patients with cancer are at risk of drug–drug interactions.
Early Access to Investigational Agents through the National Cancer Institute’s Treatment Referral Center
Although medical oncology has furthered effective cancer treatment for many decades, finding effective treatment for patients with advanced cancer is challenging. Millions of dollars support publicly funded cancer research every year, and patients expect that the latest cancer research will bring us one step closer to discovering a cure.
Impact of Pharmacists' Interventions on Prescribing Patterns for the Treatment of VTE in Patients with Cancer
Venous thromboembolism (VTE) is a common comorbidity among patients with cancer. It is often one of the initial signs for the presence of malignancy, and its presence increases the complexity of patient care within this patient population. Studies have shown that 15% to 20% of all acute VTE cases are associated with malignancy, 2% to 5% of cases are diagnosed concurrently with cancer, and 5% to 10% of cases are diagnosed during a cancer follow-up visit.1 Therefore, VTE is a significant complication affecting quality of life and patient prognosis. In fact, VTE is known to represent one of the leading causes of death in this patient population,2 and it is discovered at autopsy in at least 50% of patients with cancer.3,4 This percentage is thought to be underestimated; therefore, it is imperative to recognize this medical problem and to appropriately deploy effective treatment to reduce morbidity and mortality.
Page 6 of 7
Results 51 - 60 of 65
Results 51 - 60 of 65